In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Gennex Laboratories approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025) along with the limited review reports from statutory auditor R Pugalia & Company. On a standalone basis, revenue from operations rose about 20% year-on-year to Rs 25.64 crore (from Rs 21.33 crore), but net profit was nearly flat at Rs 4.15 crore versus Rs 4.17 crore last year, reflecting a sharp jump in raw material costs. On a consolidated basis, revenue grew around 21% YoY to Rs 34.18 crore and net profit rose about 8% to Rs 5.02 crore, helped by contribution from subsidiary Deccan Remedies Ltd. Profit-before-tax margins on a standalone basis shrank from roughly 20.7% to 17.4% due to the higher material cost. Earnings per share stood at Rs 0.179 (standalone) and Rs 0.217 (consolidated). The auditor's review report was clean with no qualifications or emphasis of matter, though the consolidated review noted that figures of the subsidiary are reviewed by another auditor.
Positive revenue momentum, especially on the consolidated side where subsidiary contribution lifted bottom line, but margin compression on standalone results signals cost pressure that investors should watch. The stock may react neutrally to mixed growth-with-flat-standalone-profit print; consolidated earnings trajectory is the key driver going forward.